Indexat a

Llicència i ús

Citacions

Altmetrics

Grant support

This work was supported by project PID2021-126304OB-C41 funded by MCIN/AEI/10.13039/501100011033/and by European Regional Development Fund - A way of doing Europe and Generalitat Valenciana (project CIPROM/2021/007) and CIBER (CB07/01/2012). There has also been the support of Institute of Health Carlos III (COV20/01209, Ministry of Science and Innovation of Spain) and grants from the Valencian Society of Pulmonology (FNCV Grant 2022 IP: Lucia Fernandez Presa; FNCV Grant Coordinated Research Project 2022 IP: Jaime Signes-Costa), U26 NMR: Biomedical Applications II platform from Nanbiosis (Research Infrastructures & Services of CIBER-BBN) and Marina Botello - Marabotto PhD grant (FPU 2020) from Spanish' government.

Anàlisi d'autories institucional

Compartir

Metabolomic Biomarkers of Pulmonary Fibrosis in COVID-19 Patients One Year After Hospital Discharge

Publicat a:Journal Of Medical Virology. 97 (3): e70289- - 2025-03-01 97(3), DOI: 10.1002/jmv.70289

Autors: Botello-Marabotto, Marina; Tarraso, Julia; Mulet, Alba; Presa-Fernandez, Lucia; Fernandez-Fabrellas, Estrella; Portal, Jose A Rodriguez; Ros, Jose A; Lozano-Vicente, Desire; Bernardos, Andrea; Martinez-Bisbal, M Carmen; Martinez-Manez, Ramon; Signes-Costa, Jaime

Afiliacions

Resum

Coronavirus disease 2019 (COVID-19) global pandemic has affected more than 600 million people up to date. The symptomatology and severity of COVID-19 are very broad, and there are still concerns about the long-term sequelae that it can have on discharged patients. The development of pulmonary fibrotic sequelae after this infection is especially worrying. Our aim was to determine if there was a metabolomic signature that could predict the development of pulmonary fibrotic sequelae. It is a multicenter prospective observation subcohort based on the COVID-FIBROTIC study. A metabolomic analysis was performed by nuclear magnetic resonance (NMR) on serum samples from patients admitted with bilateral COVID-19 pneumonia collected 2 months after hospital discharge. One year after admission, clinical, functional and radiological data were collected from these same patients. Finally, 109 patients (mean age 57.68 [DS14.03], 65.13% male) were available. Fibrotic sequelae 1 year after COVID-19 disease were found in 33% of them. Based on the NMR analysis of the serum samples, it was possible to distinguish with 80.82% of sensitivity, 72.22% of specificity and 0.83 of an area under the curve (AUC) value which patients would have radiological signs of pulmonary fibrotic pattern 1 year after sample collection. According to the metabolites participating in the discriminative model and the univariate statistics, glucose, valine, and fatty acids (& boxH;CH-CH2-CH & boxH;) were suggested as potential biomarkers of the development of pulmonary fibrotic sequelae after COVID-19.

Paraules clau